Abstract
Intensification therapy adding a boosted protease inhibitor (PI) to a failing regimen has the potential to worsen the resistance profile. Sixty-six patients included in four different boosted PI intensification studies were assessed and resistance mutations in the reverse transcriptase and protease genes were evaluated at baseline and 4 weeks after the initiation of the intensification strategy. Only one of the 66 patients developed changes in their pattern of mutations able to generate or increase resistance to new drugs.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antiretroviral Therapy, Highly Active
-
Carbamates
-
Drug Resistance, Multiple, Viral
-
Follow-Up Studies
-
Furans
-
HIV Infections / drug therapy*
-
HIV Infections / virology
-
HIV Protease / genetics*
-
HIV Protease Inhibitors / therapeutic use*
-
HIV Reverse Transcriptase / genetics*
-
HIV-1 / genetics*
-
Humans
-
Indinavir / therapeutic use
-
Lopinavir
-
Mutation*
-
Pyrimidinones / therapeutic use
-
Ritonavir / therapeutic use
-
Saquinavir / therapeutic use
-
Sulfonamides / therapeutic use
-
Treatment Failure
-
Viral Load
Substances
-
Carbamates
-
Furans
-
HIV Protease Inhibitors
-
Pyrimidinones
-
Sulfonamides
-
Lopinavir
-
amprenavir
-
Indinavir
-
HIV Reverse Transcriptase
-
HIV Protease
-
Saquinavir
-
Ritonavir